| Autor: |
Chalabianloo, Fatemeh, Høiseth, Gudrun, Vold, Jørn Henrik, Johansson, Kjell Arne, Kringen, Marianne K., Dalgard, Olav, Ohldieck, Christian, Druckrey-Fiskaaen, Karl Trygve, Aas, Christer, Løberg, Else-Marie, Bramness, Jørgen G., Fadnes, Lars Thore |
| Předmět: |
|
| Zdroj: |
Journal of Addictive Diseases; Jan-Mar2023, Vol. 41 Issue 1, p53-63, 11p |
| Abstrakt: |
There is limited knowledge on the causes of large variations in serum methadone concentrations and dose requirements. We investigated the impact of the degree of liver fibrosis on dose-adjusted steady-state serum methadone concentrations. We assessed the clinical and laboratory data of 155 Norwegian patients with opioid use disorder undergoing methadone maintenance treatment in outpatient clinics in the period 2016–2020. A possible association between the degree of liver fibrosis and dose-adjusted serum methadone concentration was explored using a linear mixed-model analysis. When adjusted for age, gender, body mass index, and genotypes of CYP2B6 and CYP3A5, the concentration-to-dose ratio of methadone did not increase among the participants with liver fibrosis (Coefficient: 0.70; 95% CI: −2.16, 3.57; P: 0.631), even among those with advanced cirrhosis (−0.50; −4.59, 3.59; 0.810). Although no correlation was found between the degree of liver stiffness and dose-adjusted serum methadone concentration, close clinical monitoring should be considered, especially among patients with advanced cirrhosis. Still, serum methadone measurements can be considered a supplement to clinical assessments, taking into account intra-individual variations. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
